SG11202007017PA - Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects - Google Patents
Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effectsInfo
- Publication number
- SG11202007017PA SG11202007017PA SG11202007017PA SG11202007017PA SG11202007017PA SG 11202007017P A SG11202007017P A SG 11202007017PA SG 11202007017P A SG11202007017P A SG 11202007017PA SG 11202007017P A SG11202007017P A SG 11202007017PA SG 11202007017P A SG11202007017P A SG 11202007017PA
- Authority
- SG
- Singapore
- Prior art keywords
- ctla
- antibodies
- adverse effects
- mutant anti
- immunotherapeutic effect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625662P | 2018-02-02 | 2018-02-02 | |
| US201862647123P | 2018-03-23 | 2018-03-23 | |
| US201862754781P | 2018-11-02 | 2018-11-02 | |
| PCT/US2019/015686 WO2019152423A1 (en) | 2018-02-02 | 2019-01-29 | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202007017PA true SG11202007017PA (en) | 2020-08-28 |
Family
ID=67479445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202007017PA SG11202007017PA (en) | 2018-02-02 | 2019-01-29 | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3746479A4 (en) |
| JP (1) | JP2021512884A (en) |
| KR (1) | KR20200118458A (en) |
| CN (1) | CN111699195A (en) |
| AU (1) | AU2019214865A1 (en) |
| CA (1) | CA3089768A1 (en) |
| IL (1) | IL276447A (en) |
| SG (1) | SG11202007017PA (en) |
| TW (1) | TW201936637A (en) |
| WO (1) | WO2019152423A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CA3117700C (en) * | 2018-10-31 | 2024-02-20 | Bioatla, Inc. | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| EP3955960A1 (en) * | 2019-04-18 | 2022-02-23 | Bristol-Myers Squibb Company | Ipilimumab variants with enhanced specificity for binding at low ph |
| WO2024056049A1 (en) * | 2022-09-16 | 2024-03-21 | 同润生物医药(上海)有限公司 | Ph-dependent anti-ctla4 antibody or antigen-binding fragment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| TWI667346B (en) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | Antibodies with modified affinity to fcrn that promote antigen clearance |
| ES2715673T3 (en) * | 2012-12-03 | 2019-06-05 | Bristol Myers Squibb Co | Improvement of the anti-cancer activity of immunomodulatory FC fusion proteins |
| WO2015058048A1 (en) * | 2013-10-18 | 2015-04-23 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| US10174113B2 (en) * | 2015-04-28 | 2019-01-08 | Bristol-Myers Squibb Company | Treatment of PD-L1-negative melanoma using an anti-PD-1 antibody and an anti-CTLA-4 antibody |
| WO2017106372A1 (en) * | 2015-12-15 | 2017-06-22 | Oncoimmune, Inc. | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof |
| EP3400023A1 (en) * | 2016-01-10 | 2018-11-14 | ModernaTX, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
-
2019
- 2019-01-29 AU AU2019214865A patent/AU2019214865A1/en active Pending
- 2019-01-29 SG SG11202007017PA patent/SG11202007017PA/en unknown
- 2019-01-29 CN CN201980010939.7A patent/CN111699195A/en active Pending
- 2019-01-29 EP EP19748152.6A patent/EP3746479A4/en active Pending
- 2019-01-29 KR KR1020207025126A patent/KR20200118458A/en unknown
- 2019-01-29 WO PCT/US2019/015686 patent/WO2019152423A1/en unknown
- 2019-01-29 JP JP2020542291A patent/JP2021512884A/en active Pending
- 2019-01-29 CA CA3089768A patent/CA3089768A1/en active Pending
- 2019-02-01 TW TW108104315A patent/TW201936637A/en unknown
-
2020
- 2020-08-02 IL IL276447A patent/IL276447A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3089768A1 (en) | 2019-08-08 |
| CN111699195A (en) | 2020-09-22 |
| JP2021512884A (en) | 2021-05-20 |
| AU2019214865A1 (en) | 2020-09-17 |
| KR20200118458A (en) | 2020-10-15 |
| EP3746479A4 (en) | 2021-11-24 |
| IL276447A (en) | 2020-09-30 |
| TW201936637A (en) | 2019-09-16 |
| WO2019152423A1 (en) | 2019-08-08 |
| EP3746479A1 (en) | 2020-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276447A (en) | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects | |
| ZA201804077B (en) | Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof | |
| IL283812B (en) | Humanized anti-human-pd-1 antibody | |
| IL282668A (en) | Humanized antibodies against c-kit | |
| IL282756A (en) | Humanized anti-sirpα antibodies | |
| SG11202007735TA (en) | Anti-her2 antibodies | |
| ZA201903896B (en) | Novel anti-human muc1 antibody fab fragment | |
| EP3880227A4 (en) | Cd25 antibodies | |
| IL281272A (en) | Humanized anti-c5 antibodies and uses thereof | |
| IL280239A (en) | Improved procoagulant antibodies | |
| EP3765078A4 (en) | Anti-gucy2c chimeric antigen receptor compositions and methods | |
| EP3825334A4 (en) | Anti-her3 humanized monoclonal antibody | |
| IL279823A (en) | Humanized antibodies against psma | |
| IL281608A (en) | Anti-human cd45rc antibodies and uses thereof | |
| SG11202103095RA (en) | Anti-human vsig4 antibodies and uses thereof | |
| GB201806084D0 (en) | Antibodies | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| GB201911213D0 (en) | Monoclonal antibodies against loricrin | |
| GB201820006D0 (en) | Humanised anti-IL17BR antibody | |
| SG11202105718TA (en) | Modified antibodies | |
| HK1245282A1 (en) | Humanized anti-cd19 antigen-binding fragment |